Alvotech Expects Minimal Impact from U.S. Tariffs on Pharmaceuticals

An update from Alvotech ( (ALVO) ) is now available.

On May 7, 2025, Alvotech announced that potential U.S. tariffs on imported pharmaceuticals are expected to have minimal impact on its 2025 revenues. The company manufactures its biosimilars in Iceland, which faces a minimum 10% tariff on goods imported to the U.S. This tariff would increase costs for customers by less than 1% of Alvotech’s expected total product revenues in 2025, as customers are responsible for transport and import duties. Alvotech’s strategic positioning and manufacturing location help mitigate the impact of these tariffs, ensuring continued cost-effective access to biosimilars for U.S. patients.

Spark’s Take on ALVO Stock

According to Spark, TipRanks’ AI Analyst, ALVO is a Underperform.

Alvotech’s overall stock score is low due to significant financial performance challenges, bearish technical indicators, and poor valuation metrics. The company’s strong revenue growth is overshadowed by its inability to achieve profitability and high financial leverage, highlighting risks of financial instability. Technical analysis confirms a downward trend, with valuation metrics reflecting these underlying issues.

To see Spark’s full report on ALVO stock, click here.

More about Alvotech

Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines. The company aims to be a leader in the biosimilar space by providing high-quality, cost-effective products. Alvotech has a diverse pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer, and has formed strategic partnerships to expand its global reach.

Average Trading Volume: 126,034

Technical Sentiment Signal: Sell

Current Market Cap: $2.41B

See more insights into ALVO stock on TipRanks’ Stock Analysis page.